Skip to main content

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.

Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, Cibas ES, Jänne PA, Krop IE

Publication: Br J Cancer (2010) • Vol 102 • Page 1495-502PMID: 20461092View on PubMed

Purpose

Two methods of circulating tumor cell (CTC) isolation, the CellSearch Epithelial kit (CEK) and the CellSearch Profile kit (CPK), were compared in terms of CTC recovery, purity, and molecular characterization in clinical specimens from patients diagnosed with metastatic cancer as well as peripheral blood specimens spiked with cancer cell lines. The paper also examined whether CTC recovery is compromised by the method of cell counting (manual, semi-automatic), the type of collection tube used, or a delay to processing, and whether CTCs isolated using the CPK method are viable and suitable for analysis by in situ hybridization and immunofluorescence.

Conclusion

CTC isolation using the CPK method resulted in significantly higher median cell counts and superior purity than the CEK method when blood from patients diagnosed with metastatic breast cancer or NSCLC were analyzed.  Differences in cell yield between the CEK and CPK methods were not a result of manual versus semi-automatic cell counting. A higher percentage of apoptotic cells were isolated using the CPK method in comparison to the CEK method, when specimens were pretreated with apoptosis-inducing agents, suggesting that the method of CTC isolation adversely affects the recovery of more fragile cell types. Further, the CPK method could reproducibly isolate pure, viable CTCs from EDTA blood specimens after a processing delay at room temperature of up to 72 hrs. Detectable levels of total and phosphorylated HER2 and EGFR was also stable among blood specimens collected in CellSave tubes that experienced a processing delay at room temperature for up to 144 h.

Studies (5)

Purpose

This study compared the sensitivity of two methods for the enumeration of circulating tumor cells (CTCs) in peripheral blood from 71 patients with metastatic NSCLC and 75 patients with metastatic breast cancer and assessed the purity of CTCs isolated by the CPK method. Blood specimens were collected into CellSave blood collection tubes and stored at room temperature until processed (≤ 72 h). For the CEK method, specimens were processed with the CellSearch system according to the manufacturer’s instructions and analyzed by semi-automated counting of labelled CTCs. For the CPK method, specimens were collected in a dilution buffer and immediately prepared as cytospin preparations by centrifugation at 500 x g for 5 min with a cytology filter. Slides were fixed with methanol for analysis by immunofluorescence (cytokeratin, CD45, DAPI, HER2, Phospho-HER2, EGFR, and Phospho-EGFR) or fixed with methanol:acetic acid (3:1) for fluorescent in situ hybridization (FISH) analysis of cytokeratin, CD45, DAPI, MET, EGFR, pEGFR, HER2, and pHER and manual counting using a standard fluorescence microscope.

Summary of Findings

Median cell counts from the CPK method were significantly higher than those obtained using the CEK method for specimens from breast cancer patients (116.5/7.5 ml of blood compared to 4/7.5 ml of blood, 29-fold difference, P<0.0001) and patients with NSCLC (145/7.5 ml of blood compared to 4/7.5 ml of blood, 36-fold difference, P<0.0001). Lower yields of cells isolated by CEK were not due to method of cell counting (manual vs semi-automatic) as differences in median cell counts were not statistically significant between cells counted using the semi-automated CEK method and those counted manually (4 CTCs versus 5 CTCs/7.5 ml of blood) in specimens from breast cancer and NSCLC patients. Further, a comparison between cells counts on a per patient basis revealed a strong correlation between those obtained using the semi-automated CEK method and the manual CEK method in breast cancer specimens (R2=0.9930) and lung cancer specimens (R2=0.7200).

The purity of cells isolated by the CPK method from 30 NSCLC and 30 breast cancer patients revealed that 60% of cells were identified as tumor cells (DAPI+, cytokeratin+, CD45-; range: 21–95%), 6% were white blood cells (DAPI+, cytokeratin-, CD45+; range: 1–22%), and 32% could not be classified as either tumor cells or white blood cells (DAPI+ only, range: 5–68%) which corresponds to a median absolute number of cytokeratin positive cells of 280 per specimen (range 20–20,000) and a median of 34 (range 20–476) CD45 positive cells per specimen. Fluorescence-activated cell sorting on eight NSCLC and three breast cancer patients revealed similar results for percentage of cytokeratin positive cells (61%; range 35–77%) but a lower percentage of CD45 positive cells (1%; range 0–7%). FISH analysis of the CPK-isolated CTCs from 24 patients with HER2 positive breast cancer resulted in 72% of cells with a HER2 gene copy number ≥4 and only 3% of the cells had two copies of HER2. In contrast, only 5% of CPK-isolated cells from the six HER2-negative breast cancer patients had ≥4 copies of HER2 and 95% of cells had two copies of HER2. Similarly, 53% of blood specimens from 30 NSCLC patients had ≥4 copies of EGFR, 13% had ≥4 copies CEP 7, and only 5% had two copies of EGFR and CEP 7. Analysis of peripheral blood specimens from 40 healthy volunteers with either the CEK semi-automated enumeration or with the CPK manual count resulted in no CTCs (CD45 negative/cytokeratin positive) and a median of five CD45 positive/cytokeratin negative cells (indicative of white blood cells) per 7.5 ml of blood (range: 0–50) with only two gene copies of CEP7/EGFR or HER2 as detected by FISH analysis were isolated by the CPK method.

  • Biospecimens

    FluidBlood
  • Preservation Types

    Other Preservative
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    Cell count/volumeFluorescent microscopy
    ProteinFluorescent microscopy
    ProteinFlow cytometry
    DNAFISH
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen Aliquots and ComponentsCell capture method
    CellSearch Epithelial Cell Kit
    CellSearch Profile Kit
    Fluorescent microscopy SpecificDetection method
    Manual counting
    Semi-automatic counting
    Fluorescent microscopy SpecificTargeted peptide/protein
    CD45
    DAPI
    cytokeratin
    FISH SpecificTargeted nucleic acid
    CD45
    CEP 7
    DAPI
    EGFR
    HER2
    cytokeratin
    Flow cytometry SpecificTargeted peptide/protein
    CD45
    cytokeratin